Obesity and vascular dysfunction: The fat-e of rich and poor

British Journal of Pharmacology

Volumn 165, Issue 3, 2012, Pages 541-543

  Vanhoutte, Paul M ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITRIC OXIDE;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LIPID STORAGE; OBESITY; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

DIETARY FATS; ENDOTHELIUM, VASCULAR; HUMANS; OBESITY; SOCIOECONOMIC FACTORS; VASCULAR DISEASES;

EID: 84855705868     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01788.x     Document Type: Editorial

References (36)

1. Aghamohammadzadeh R, Witners S, Lynch F, Greenstein A, Malik R, Heagerty A, (2012). Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol 165: 670-682.
2. Auger FA, D'Orleans-Juste P, Germain L, (2007). Adventitia contribution to vascular contraction: hints provided by tissue-engineered substitutes. Cardiovasc Res 75: 669-678. (Pubitemid 47238741)
3. Bagi Z, Feher A, Cassuto J, (2012). Microvascular responsiveness in obesity: implications for therapeutic intervention. Br J Pharmacol 165: 544-560.
4. Barton M, Baretella O, Meyer M, (2012). Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. Br J Pharmacol 165: 591-602.
5. Bays HE, (2011). Adiposopathy: is 'Sick Fat' a cardiovascular disease? J Am Coll Cardiol 57: 2461-2473.
6. Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer XP, Ronnett GV, Tan TMM, et al,. (2008). The obesity epidemic-pharmacological challenges. Mol Interv 8: 82-98.
7. Brandes RP, (2007). The fatter the better? Perivascular adipose tissue attenuates vascular contraction through different mechanisms. Br J Pharmacol 151: 303-304. (Pubitemid 46842670)
8. Campia U, Tesauro M, Cardillo C, (2012). Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165: 561-573.
9. De Mey JG, Vanhoutte PM, (1982). Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 51: 439-447. (Pubitemid 12034483)
10. Félétou M, Vanhoutte PM, (2009). EDHF: an update. Clin Sci 117: 139-155.
11. Furchgott RF, Vanhoutte PM, (1989). Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007-2017.
12. Furchgott RF, Zawadzki JV, (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376. (Pubitemid 11169009)
13. Furuhashi M, Hotamisligil GS, (2008). Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489-503. (Pubitemid 351767117)
14. Garland CJ, Weston AH, (2011). The vascular endothelium: still amazing us 30 years on. Br J Pharmacol 164: 837-838.
15. Gollasch M, (2012). Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 165: 633-642.
16. Haslam DW, James WP, (2005). Obesity. Lancet 366: 1197-1209. (Pubitemid 41393598)
17. Hui X, Lam K, Vanhoutte P, Xu A, (2012). Adiponectin and cardiovascular health: an update. Br J Pharmacol 165: 574-590.
18. Ichiki T, (2010). Perivascular adipose tissue, a Janus-faced regulator of vascular function. Circ J 74: 1300-1301.
19. Jamaluddin MDS, Weakley S, Yao Q, Chen C, (2012). Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 165: 622-632.
20. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS, (2009). Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 296: E1210-E1229.
21. Miao CY, Li ZY, (2012). The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol 165: 643-658.
22. Payne G, Kohr M, Tune J, (2012). Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol 165: 659-669.
23. Rodriguez-Pascual F, Busnadiego O, Lagares D, Lamas S, (2011). Role of endothelin in the cardiovascular system. Pharmacol Res 63: 463-472.
24. Rubanyi GM, (2011). The discovery of endothelin: the power of bioassay and the role of serendipity in the discovery of endothelium-derived vasoactive substances. Pharmacol Res 63: 448-454.
25. Shepherd JT, Vanhoutte PM, (1979). The Human Cardiovascular System. Facts and Concepts. Raven Press: New York, pp. 1-351.
26. Shibata R, Ouchi N, Murohara T, (2009). Adiponectin and cardiovascular disease. Circ J 73: 608-614.
27. Vanhoutte PM, (1974). Inhibition by acetylcholine of adrenergic neurotransmission in vascular smooth muscle. Circ Res 34: 317-326.
28. Vanhoutte PM, (1988). The endothelium-modulator of vascular smooth-muscle tone. N Engl J Med 319: 512-513.
29. Vanhoutte PM, (2009). How we learned to say NO. Arterioscler Thromb Vasc Biol 29: 1156-1160.
30. Vanhoutte PM, (2011). Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension 57: 526-531.
31. Vanhoutte PM, Tang E, Félétou M, Shimokawa H, (2009). Endothelial dysfunction and vascular disease. Acta Physiol 196: 193-222.
32. Vanhoutte PM, Verbeuren TJ, Webb RC, (1981). Local modulation of the adrenergic neuroeffector interaction in the blood vessel wall. Physiol Rev 61: 151-247.
33. Wang Y, (2012). Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol 165: 603-621.
34. Wild S, Roglic G, Green A, Sicree R, King H, (2004). Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care 27: 1047-1053. (Pubitemid 38579764)
35. Woodhouse R, (2008). Obesity in art: a brief overview. Front Horm Res 36: 271-286.
36. Zhu W, Cheng KKY, Vanhoutte PM, Lam KSL, Xu A, (2008). Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 114: 361-374. (Pubitemid 351397385)